Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock Has Consensus Target Price of $12.77 According to Brokerages

Key Points

• Taysha Gene Therapies has a consensus “Buy” rating from 15 analysts, with 12 buy ratings, two strong-buy ratings and one sell rating. The average 12-month price target is $12.77.
• TSHA shares opened at $4.13, well below the analyst target, with a market capitalization of approximately $1.35 billion. The stock has traded between $3.45 and $7.30 over the past year.
• Institutional investors own 77.7% of the company, while several major funds increased their positions. Taysha, a clinical-stage biotechnology company developing gene therapies for central nervous system diseases, reported a quarterly loss of $0.13 per share, missing estimates by $0.02.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has been assigned an average rating of "Buy" from the fifteen research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, twelve have given a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $12.77.

A number of research firms have commented on TSHA. The Goldman Sachs Group boosted their price target on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Tuesday, July 21st. Wolfe Research began coverage on shares of Taysha Gene Therapies in a research report on Thursday, September 17th. They set an "outperform" rating on the stock. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Taysha Gene Therapies in a report on Monday, September 21st.

Hedge Funds Weigh In On Taysha Gene Therapies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TSHA. Wellington Management Group LLP boosted its stake in Taysha Gene Therapies by 534.7% during the 2nd quarter. Wellington Management Group LLP now owns 3,975,605 shares of the company's stock valued at $27,074,000 after purchasing an additional 3,349,244 shares during the period. ADAR1 Capital Management LLC boosted its stake in Taysha Gene Therapies by 19.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 2,979,429 shares of the company's stock valued at $13,318,000 after buying an additional 483,620 shares in the last quarter. Seven Fleet Capital Management LP boosted its stake in shares of Taysha Gene Therapies by 140.4% in the 2nd quarter. Seven Fleet Capital Management LP now owns 1,504,400 shares of the company's stock valued at $9,940,000 after purchasing an additional 878,692 shares in the last quarter. Rice Hall James & Associates LLC boosted its holdings in shares of Taysha Gene Therapies by 53.0% in the 1st quarter. Rice Hall James & Associates LLC now owns 1,944,671 shares of the company's stock worth $8,693,000 after acquiring an additional 674,026 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Taysha Gene Therapies by 45.5% in the first quarter. Bank of America Corp DE now owns 1,677,046 shares of the company's stock valued at $7,496,000 after buying an additional 524,366 shares during the last quarter. Institutional investors and hedge funds own 77.70% of the company's stock.

Taysha Gene Therapies Stock Down 2.1%

Shares of Taysha Gene Therapies stock opened at $4.13 on Friday. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of -9.83 and a beta of 1.19. Taysha Gene Therapies has a twelve month low of $3.45 and a twelve month high of $7.30. The company has a fifty day moving average price of $4.82 and a 200 day moving average price of $5.31. The company has a current ratio of 17.76, a quick ratio of 17.76 and a debt-to-equity ratio of 0.13.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). Equities research analysts forecast that Taysha Gene Therapies will post -0.52 earnings per share for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. The company uses adeno-associated virus (AAV) delivery technologies and other genetic medicine approaches to address disorders that currently have limited or no effective treatment options.

Taysha's development programs have included TSHA-102 for Rett syndrome, TSHA-101 for GM1 gangliosidosis and TSHA-120 for giant axonal neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.